Revenue from operations rose 7% yoy to Rs115.58cr
Q1FY22 revenue from operations grew by 18% yoy and 17% qoq to Rs108.13cr. PBT grew by 50% yoy and 115% qoq.
Full Year Revenue up by 4% yoy to Rs389.14cr and PBT up by 47% to Rs53.58cr over last year.
Revenue from operations grew by 14% yoy to Rs107.60cr. For 9MFY21 PBT from operations stood at Rs44.63cr up from Rs33.31cr.
The rating on long-term loans Rs35cr was upgraded to ICRA A from ICRA A-. The outlook remained stable.
Around 71 lakh shares or 42.9% equity changed hands in pre-market trade.
In the pre-open market today, nearly 2.45 mn shares of the company were traded at Rs452.81 on the BSE, data available showed.
The company reported its net profit jumped 300% to Rs 10.3 crore in the quarter ended September 2016 as against Rs 2.6 crore during the
The company yesterday said that it has signed an agreement to acquire seven prescription brands from Sun Pharmaceuticals Industries Ltd
The company said that it has signed an agreement to acquire seven prescription brands from Sun Pharmaceuticals Industries for Rs.41 cro
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity